In short
BI 1015550, also known as Nerandomilast, is a drug currently being studied in various clinical trials. These trials aim to investigate its safety, tolerability, and how it's processed in the body (pharmacokinetics) in different populations, including healthy volunteers and those with specific health conditions. The studies explore different dosages, formulations, and administration methods to better understand the drug's potential therapeutic use.
At a glance
- Drug Name
- BI 1015550 (Nerandomilast)
- Study Types
- Safety, tolerability, pharmacokinetics
- Populations Studied
- Healthy volunteers, individuals with renal impairment
- Formulations
- Powder for oral solution, tablets
- Key Measurements
- AUC, Cmax, adverse events
- Special Considerations
- Food effects, different dosages, bioequivalence of formulations
- Study Designs
- Single-dose, multiple-dose, crossover, parallel group
What is BI 1015550?
BI 1015550, also known as Nerandomilast, is an investigational drug being developed by Boehringer Ingelheim for the treatment of pulmonary fibrosis. It is currently undergoing clinical trials to evaluate its safety and effectiveness in treating various forms of lung fibrosis, particularly idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).
What Conditions Does BI 1015550 Treat?
BI 1015550 is primarily being studied for the treatment of two main conditions:
- Idiopathic Pulmonary Fibrosis (IPF): This is a chronic, progressive lung disease characterized by the formation of scar tissue in the lungs, making it difficult to breathe.
- Progressive Pulmonary Fibrosis (PPF): This term encompasses various forms of progressive fibrotic lung diseases that share similarities with IPF.
Both of these conditions involve the gradual scarring of lung tissue, which can lead to breathing difficulties and reduced quality of life for patients.
How Does BI 1015550 Work?
While the exact mechanism of action is not fully described in the provided clinical trial information, BI 1015550 is being studied for its potential to slow down the worsening of lung function in patients with pulmonary fibrosis. The drug is believed to have anti-fibrotic properties, which means it may help reduce the formation of scar tissue in the lungs.
Clinical Trials and Research
BI 1015550 is currently being evaluated in several clinical trials:
- Phase 2 Trial: A 12-week study was conducted to test how BI 1015550 affects lung function in people with IPF. This trial compared the drug to a placebo and included patients who were already taking standard IPF medications like nintedanib or pirfenidone.
- Phase 3 Trial: A longer-term study (at least 52 weeks) is ongoing to further evaluate the efficacy and safety of BI 1015550 in IPF patients. This trial is testing different doses of the drug against a placebo.
- Extension Study: An open-label extension trial is being conducted to assess the long-term safety and efficacy of BI 1015550 in patients with IPF and PPF who have completed previous studies with the drug.
These trials are measuring various outcomes, including changes in lung function (measured by Forced Vital Capacity or FVC), time to disease progression, and quality of life measures.
How is BI 1015550 Administered?
BI 1015550 is taken orally in the form of tablets. In clinical trials, it has been administered in various ways:
- Twice daily dosing (morning and evening)
- Different dosage strengths are being tested (e.g., low dose and high dose)
- Some trials have used a combination of tablet strengths (e.g., 1x 6mg tablet + 1x 12mg tablet) to achieve the desired daily dose
The exact dosing regimen may vary depending on the specific trial and patient characteristics.
Potential Side Effects
As BI 1015550 is still in clinical trials, the full range of potential side effects is not yet known. However, the trials are closely monitoring for any adverse events (unwanted effects) that may occur during treatment. Patients participating in these studies are regularly checked for any health issues that may arise.
Future Prospects
BI 1015550 shows promise as a potential new treatment option for patients with pulmonary fibrosis. If successful in clinical trials, it could offer an alternative or complementary therapy to existing treatments. The ongoing long-term studies will provide more information about its effectiveness and safety over extended periods.
It's important to note that as an investigational drug, BI 1015550 is not yet approved for general use. Patients interested in this treatment should discuss current clinical trial opportunities with their healthcare providers.